Novartis recently announced long-term results from the ongoing phase 3 NEPTUNUS extension study of ianalumab in Sjögren’s disease (SD).
These findings were presented at the American College of Rheumatology (ACR) Convergence 2026.
Let’s start with Sjögren’s disease.
SD is a serious, systemic autoimmune disease in which B-cell dysfunction contributes to inflammation, tissue damage and symptoms including dryness, fatigue, pain and organ involvement—substantially impacting patients’ daily lives.
While the chronic autoimmune disorder impacts the entire body, it can be detected during a comprehensive eye exam—and dry eye is a hallmark feature.
- Other ocular-related signs can include blurry vision, burning or tinging eyes, light sensitivity (photophobia), contact lens discomfort, and blepharitis.
And are there any SD-specific treatments available?
While there are FDA-approved medications that target managing specific symptoms associated with SD, there’s currently no FDA-approved, disease-modifying treatment that addresses the root autoimmune causes of the disease.
Got it. Now talk more about Novartis’ asset.
The candidate was originally developed by the German biopharma company MorphoSys AG prior to being acquired by Novartis in 2024.
As for the drug itself: ianalumab is an investigational fully human monoclonal antibody designed to target B-cell activating factor receptor (BAFF-R), which drives autoimmune inflammation in diseases such as Sjögren’s.
- Its dual mechanism of action involves depleting B-cells and blocking BAFF-R signaling to reduce disease activity—see here for a more detailed breakdown of how this works.
- Its mode of delivery: Via a subcutaneous injection.
Is SD its only indication target?
It’s not. In addition to SD, Novartis is also investigating ianalumab for its ability to treat other B-cell driven diseases, such as:
- Immune thrombocytopenia (ITP)
- Systemic lupus erythematosus (SLE)
- Lupus nephritis (LN)
- Systemic sclerosis (SSc)
So what does its regulatory status look like?
This past January, the FDA granted Breakthrough Therapy Designation to the candidate in addition to the Fast Track Designation it received in 2016.
Noted. Is there any clinical data available yet?
Findings from two global multicenter, pivotal phase 3 trials—NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214)—have demonstrated promising results thus far in evaluating the candidate’s efficacy and safety among 700+ adult SD patients.
Case in point: Data presented in October 2025 determined a 300 mg monthly dose of ianalumab (versus placebo) delivered a clinically meaningful benefit, with both trials showing:
- improvement in disease activity
- reductions in treatment and patient burden
Can you be more specific?
Ianalumab was found to have a favorable safety profile with “an overall incidence of adverse events (AEs) and serious AEs (SAEs) comparable to placebo in both studies.”
In fact, the NEPTUNUS trials were referred to as the first phase 3 studies on SD in which a “treatment significantly improved disease activity” and demonstrated ianalumab’s potential to provide a clinically meaningful benefit to patients.
- See here for more from this data readout.
Tell me more about these NEPTUNUS trials.
The two 52-week, double-blind, randomized, placebo-controlled trials involving patients with active SD.
- Patients in the NEPTUNUS-1 trial (n=275) were assigned in a 1:1 ratio to receive subcutaneous (SC) ianalumab (300 mg monthly) or placebo
- Patients in the NEPTUNUS-2 trial (n=504) were assigned in a 1:1:1 ratio to receive 300 mg of ianalumab monthly or every 3 months or placebo.
What were the main outcome measures?
The primary endpoint for both trials was the change from baseline in the score on the European Alliance of Associations for Rheumatology (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI) at week 48 (scores range from 0 to 123, with higher scores indicating greater disease activity).
The first key secondary endpoint in the hierarchical plan for the NEPTUNUS-1 trial was an ESSDAI response (≥5-point reduction) at week 48.
- And for NEPTUNUS-2: the change from baseline in the score on the Sjögren’s Syndrome Symptom Diary (SSSD) or EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) at week 48.
Let’s dig into the results.
The data showed that the reduction in systemic disease activity continued to deepen from week 48 through week 108 among patients who continued ianalumab 300 mg monthly, as measured by EULAR ESSDAI.
More details on the ESSDAI reductions: At week 108 a mean reduction from core-study baseline of 7.5 points was observed in the group that continued ianalumab monthly and 6.5 points in the group that switched from placebo to ianalumab monthly at week 60.
- This translated to a between-group difference of −1.3 points (95% confidence interval [CI], −2.6 to 0.0; P=0.0496) in NEPTUNUS-1 and −1.0 points (95% CI, −2.0 to 0.0; P=0.04) in NEPTUNUS-2.
Note: No significant differences in the incidence of an ESSDAI response or in the change from baseline in SSSD or ESSPRI scores were observed at week 48.
Were there any new safety signals?
Nope. As in previous October 2025 results, the incidence of SAEs was similar between ianalumab and placebo.
Also: Nonserious local injection-site and systemic injection-related reactions were more common in the ianalumab groups.
Anything else?
Low disease activity (LDA) rates increased from 57.1% to 65.1% in the continuous ianalumab monthly group between weeks 48 and 108.
- LDA rates increased from 50.4% to 60.9% in patients who switched from placebo to ianalumab monthly at week 60.
Among patients with stimulated salivary flow greater than 0.4 mL/min at baseline, improvements were maintained through week 96 in the continuous ianalumab monthly group and observed after patients switched from placebo to ianalumab at week 60.
Plus: improvements in physician- and patient-reported measures and symptoms were sustained through week 108 among patients who continued ianalumab monthly, as measured by ESSPRI and SSSD, and were observed following the switch from placebo to ianalumab at week 60.
Any comments from the company?
“These findings strengthen the growing body of evidence for ianalumab and reinforce our commitment to advancing a targeted treatment that can improve care for people living with SD,” stated Angelika Jahreis, global head, Development, Immunology, Novartis.
So when can we expect an update?
Ianalumab is currently under review by regulatory authorities in multiple countries, including the U.S., “where a decision from the FDA is expected this year,” the company noted.
In addition: the NEPTUNUS extension study is ongoing to continue evaluating the longer-term efficacy, safety, and tolerability of ianalumab.
Any other updates?
Before we go: Last week Amgen announced positive results from the phase 3 OASIZ-301 study (NCT06104124) of dazodalibep in SD, noting it was “the only global phase 3 trial to demonstrate clinically meaningful improvements in systemic disease activity and symptoms in patients with SD.”
- Full results were presented during a late-breaking session (LB22) at the ACR Convergence 2026.
With things in the SD pipeline heating up, make sure to stay tuned for more updates!